Core Viewpoint - OneMedNet Corporation has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its periodic reports for the fiscal quarters ended March 31, June 30, and September 30, 2024, allowing the company to focus on business growth moving forward [1][6]. Company Developments - The company has appointed Bob Golden as interim Chief Financial Officer to enhance financial reporting processes and has hired Margaret Nash as Director of Business Development and Michael Wong as Vice President of Marketing to strengthen its commercial presence [6]. - OneMedNet has raised approximately $6.4 million in private placements to improve liquidity and is implementing a Bitcoin treasury management strategy [6]. - The company has refreshed its Board of Directors with three new members who possess relevant industry and financial expertise [6]. Strategic Initiatives - OneMedNet's platform addresses diverse clinical requirements across various domains, including rare diseases, central nervous system disorders, oncology, cardiology, and women's health, aiming to enhance patient outcomes and drive healthcare innovation [4]. - The company is enhancing its Data De-Identification and curation service using Generative AI and deploying its 2.0 generation indexer, OMNi, to improve data searching and indexing efficiency [6]. - OneMedNet is positioned to capitalize on the growing Real World Data market, leveraging its proprietary iRWD™ platform that manages diverse clinical data types from over 1,400 healthcare system and provider sites [9][10].
OneMedNet Regains Compliance with NASDAQ Periodic Filing Requirements